nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydroxychloroquine—TLR7—prostate gland—urinary bladder cancer	0.0308	0.348	CbGeAlD
Hydroxychloroquine—TLR7—female reproductive system—urinary bladder cancer	0.0168	0.19	CbGeAlD
Hydroxychloroquine—TLR7—vagina—urinary bladder cancer	0.0152	0.172	CbGeAlD
Hydroxychloroquine—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.0138	0.0486	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—urine—urinary bladder cancer	0.011	0.124	CbGeAlD
Hydroxychloroquine—TLR7—lymph node—urinary bladder cancer	0.00983	0.111	CbGeAlD
Hydroxychloroquine—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00896	0.0316	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00749	0.0265	CbGpPWpGaD
Hydroxychloroquine—TLR9—PI3K Cascade—TSC1—urinary bladder cancer	0.00705	0.0249	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll-Like Receptors Cascades—BIRC3—urinary bladder cancer	0.00644	0.0228	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00636	0.0225	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-mediated signalling—TSC1—urinary bladder cancer	0.00589	0.0208	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events—TSC1—urinary bladder cancer	0.00573	0.0203	CbGpPWpGaD
Hydroxychloroquine—TLR7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—S100B—urinary bladder cancer	0.00569	0.0201	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—TSC1—urinary bladder cancer	0.00568	0.0201	CbGpPWpGaD
Hydroxychloroquine—TLR7—MyD88 dependent cascade initiated on endosome—S100B—urinary bladder cancer	0.00559	0.0198	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—TSC1—urinary bladder cancer	0.00553	0.0196	CbGpPWpGaD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—TSC1—urinary bladder cancer	0.00553	0.0196	CbGpPWpGaD
Hydroxychloroquine—Chloroquine—TNF—urinary bladder cancer	0.00544	1	CrCbGaD
Hydroxychloroquine—TLR7—Toll Like Receptor 9 (TLR9) Cascade—S100B—urinary bladder cancer	0.0054	0.0191	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll-like Receptor Signaling Pathway—IFNA2—urinary bladder cancer	0.00525	0.0186	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00516	0.0182	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll-Like Receptors Cascades—BIRC3—urinary bladder cancer	0.00509	0.018	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—TSC1—urinary bladder cancer	0.0046	0.0162	CbGpPWpGaD
Hydroxychloroquine—TLR9—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—S100B—urinary bladder cancer	0.0045	0.0159	CbGpPWpGaD
Hydroxychloroquine—TLR9—MyD88 dependent cascade initiated on endosome—S100B—urinary bladder cancer	0.00442	0.0156	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll Like Receptor 9 (TLR9) Cascade—S100B—urinary bladder cancer	0.00427	0.0151	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll-like Receptor Signaling Pathway—IFNA2—urinary bladder cancer	0.00415	0.0147	CbGpPWpGaD
Hydroxychloroquine—TLR7—Regulation of toll-like receptor signaling pathway—IFNA2—urinary bladder cancer	0.0041	0.0145	CbGpPWpGaD
Hydroxychloroquine—TLR9—PI3K Cascade—FGFR3—urinary bladder cancer	0.00395	0.014	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll-Like Receptors Cascades—S100B—urinary bladder cancer	0.00383	0.0136	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-mediated signalling—FGFR3—urinary bladder cancer	0.0033	0.0117	CbGpPWpGaD
Hydroxychloroquine—TLR9—Regulation of toll-like receptor signaling pathway—IFNA2—urinary bladder cancer	0.00324	0.0115	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events—FGFR3—urinary bladder cancer	0.00321	0.0114	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—FGFR3—urinary bladder cancer	0.00318	0.0113	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—PRSS3—urinary bladder cancer	0.00313	0.0111	CbGpPWpGaD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—FGFR3—urinary bladder cancer	0.0031	0.011	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—FGFR3—urinary bladder cancer	0.0031	0.011	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll-Like Receptors Cascades—S100B—urinary bladder cancer	0.00303	0.0107	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—renal system—urinary bladder cancer	0.00269	0.0304	CbGeAlD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—IGF1—urinary bladder cancer	0.00268	0.00946	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—IGF1—urinary bladder cancer	0.00261	0.00921	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—FGFR3—urinary bladder cancer	0.00258	0.00911	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—PRSS3—urinary bladder cancer	0.00247	0.00874	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00247	0.00873	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll-like Receptor Signaling Pathway—CXCL8—urinary bladder cancer	0.00244	0.00863	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00244	0.00862	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—female reproductive system—urinary bladder cancer	0.00216	0.0244	CbGeAlD
Hydroxychloroquine—TLR7—Innate Immune System—BIRC3—urinary bladder cancer	0.00209	0.00737	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.002	0.00708	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll-like Receptor Signaling Pathway—CXCL8—urinary bladder cancer	0.00193	0.00682	CbGpPWpGaD
Hydroxychloroquine—TLR7—Regulation of toll-like receptor signaling pathway—CXCL8—urinary bladder cancer	0.00191	0.00674	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—PRSS3—urinary bladder cancer	0.00182	0.00644	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—VHL—urinary bladder cancer	0.00174	0.00614	CbGpPWpGaD
Hydroxychloroquine—TLR7—Toll-like Receptor Signaling Pathway—TNF—urinary bladder cancer	0.0017	0.00601	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—BIRC3—urinary bladder cancer	0.00165	0.00583	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—MT2A—urinary bladder cancer	0.00163	0.00577	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-mediated signalling—KRAS—urinary bladder cancer	0.00154	0.00545	CbGpPWpGaD
Hydroxychloroquine—TLR9—Regulation of toll-like receptor signaling pathway—CXCL8—urinary bladder cancer	0.00151	0.00533	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events—KRAS—urinary bladder cancer	0.0015	0.0053	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—KRAS—urinary bladder cancer	0.00149	0.00525	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—KRAS—urinary bladder cancer	0.00145	0.00512	CbGpPWpGaD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—KRAS—urinary bladder cancer	0.00145	0.00512	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—PRSS3—urinary bladder cancer	0.00144	0.00509	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—VHL—urinary bladder cancer	0.00137	0.00485	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.00136	0.00482	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00134	0.00475	CbGpPWpGaD
Hydroxychloroquine—TLR9—Toll-like Receptor Signaling Pathway—TNF—urinary bladder cancer	0.00134	0.00475	CbGpPWpGaD
Hydroxychloroquine—TLR7—Regulation of toll-like receptor signaling pathway—TNF—urinary bladder cancer	0.00133	0.00469	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—IFNA2—urinary bladder cancer	0.00131	0.00464	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-mediated signalling—HRAS—urinary bladder cancer	0.00131	0.00463	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.00129	0.00457	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.00129	0.00457	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—MT2A—urinary bladder cancer	0.00129	0.00456	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events—HRAS—urinary bladder cancer	0.00128	0.00451	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00127	0.0045	CbGpPWpGaD
Hydroxychloroquine—TLR9—IRS-related events triggered by IGF1R—HRAS—urinary bladder cancer	0.00126	0.00447	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—S100B—urinary bladder cancer	0.00124	0.00439	CbGpPWpGaD
Hydroxychloroquine—TLR9—IGF1R signaling cascade—HRAS—urinary bladder cancer	0.00123	0.00435	CbGpPWpGaD
Hydroxychloroquine—TLR9—Insulin receptor signalling cascade—HRAS—urinary bladder cancer	0.00123	0.00435	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—BIRC3—urinary bladder cancer	0.00122	0.0043	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—KRAS—urinary bladder cancer	0.0012	0.00425	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.00118	0.00418	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00117	0.00412	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.00106	0.00376	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00105	0.00371	CbGpPWpGaD
Hydroxychloroquine—TLR9—Regulation of toll-like receptor signaling pathway—TNF—urinary bladder cancer	0.00105	0.00371	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—IFNA2—urinary bladder cancer	0.00104	0.00367	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling by Insulin receptor—HRAS—urinary bladder cancer	0.00102	0.00361	CbGpPWpGaD
Hydroxychloroquine—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.001	0.00161	CcSEcCtD
Hydroxychloroquine—Anorexia—Gemcitabine—urinary bladder cancer	0.001	0.00161	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—RBX1—urinary bladder cancer	0.000998	0.00353	CbGpPWpGaD
Hydroxychloroquine—Urticaria—Thiotepa—urinary bladder cancer	0.000992	0.00159	CcSEcCtD
Hydroxychloroquine—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00099	0.00159	CcSEcCtD
Hydroxychloroquine—Vertigo—Etoposide—urinary bladder cancer	0.000987	0.00158	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000987	0.00158	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000987	0.00158	CcSEcCtD
Hydroxychloroquine—Anorexia—Fluorouracil—urinary bladder cancer	0.000984	0.00158	CcSEcCtD
Hydroxychloroquine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000984	0.00158	CcSEcCtD
Hydroxychloroquine—Leukopenia—Etoposide—urinary bladder cancer	0.000983	0.00158	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—S100B—urinary bladder cancer	0.000982	0.00347	CbGpPWpGaD
Hydroxychloroquine—Oedema—Cisplatin—urinary bladder cancer	0.000979	0.00157	CcSEcCtD
Hydroxychloroquine—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.00097	0.00156	CcSEcCtD
Hydroxychloroquine—Cardiac failure—Doxorubicin—urinary bladder cancer	0.00097	0.00156	CcSEcCtD
Hydroxychloroquine—Mood swings—Epirubicin—urinary bladder cancer	0.000969	0.00155	CcSEcCtD
Hydroxychloroquine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000966	0.00155	CcSEcCtD
Hydroxychloroquine—Ataxia—Epirubicin—urinary bladder cancer	0.000962	0.00154	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—BIRC3—urinary bladder cancer	0.000961	0.0034	CbGpPWpGaD
Hydroxychloroquine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00096	0.00154	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000958	0.00154	CcSEcCtD
Hydroxychloroquine—Convulsion—Etoposide—urinary bladder cancer	0.000952	0.00153	CcSEcCtD
Hydroxychloroquine—Skin disorder—Cisplatin—urinary bladder cancer	0.000951	0.00153	CcSEcCtD
Hydroxychloroquine—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000944	0.00152	CcSEcCtD
Hydroxychloroquine—Eosinophilia—Methotrexate—urinary bladder cancer	0.000935	0.0015	CcSEcCtD
Hydroxychloroquine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000934	0.0015	CcSEcCtD
Hydroxychloroquine—Somnolence—Gemcitabine—urinary bladder cancer	0.000933	0.0015	CcSEcCtD
Hydroxychloroquine—Anorexia—Cisplatin—urinary bladder cancer	0.000933	0.0015	CcSEcCtD
Hydroxychloroquine—Affect lability—Doxorubicin—urinary bladder cancer	0.000931	0.00149	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000929	0.00149	CcSEcCtD
Hydroxychloroquine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000921	0.00148	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00092	0.00148	CcSEcCtD
Hydroxychloroquine—Somnolence—Fluorouracil—urinary bladder cancer	0.000918	0.00147	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000913	0.00146	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000907	0.00145	CcSEcCtD
Hydroxychloroquine—Fatigue—Gemcitabine—urinary bladder cancer	0.000905	0.00145	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—FGFR3—urinary bladder cancer	0.000903	0.00319	CbGpPWpGaD
Hydroxychloroquine—Muscular weakness—Epirubicin—urinary bladder cancer	0.000902	0.00145	CcSEcCtD
Hydroxychloroquine—Pain—Gemcitabine—urinary bladder cancer	0.000898	0.00144	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000897	0.00144	CcSEcCtD
Hydroxychloroquine—Pancytopenia—Methotrexate—urinary bladder cancer	0.000897	0.00144	CcSEcCtD
Hydroxychloroquine—Mood swings—Doxorubicin—urinary bladder cancer	0.000896	0.00144	CcSEcCtD
Hydroxychloroquine—Asthenia—Thiotepa—urinary bladder cancer	0.000896	0.00144	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000891	0.00143	CcSEcCtD
Hydroxychloroquine—Ataxia—Doxorubicin—urinary bladder cancer	0.00089	0.00143	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—HDAC4—urinary bladder cancer	0.000888	0.00314	CbGpPWpGaD
Hydroxychloroquine—Pruritus—Thiotepa—urinary bladder cancer	0.000883	0.00142	CcSEcCtD
Hydroxychloroquine—Pain—Fluorouracil—urinary bladder cancer	0.000883	0.00142	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000878	0.00141	CcSEcCtD
Hydroxychloroquine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000875	0.0014	CcSEcCtD
Hydroxychloroquine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000874	0.0014	CcSEcCtD
Hydroxychloroquine—Skin disorder—Etoposide—urinary bladder cancer	0.000871	0.0014	CcSEcCtD
Hydroxychloroquine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000864	0.00139	CcSEcCtD
Hydroxychloroquine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000862	0.00138	CcSEcCtD
Hydroxychloroquine—Anorexia—Etoposide—urinary bladder cancer	0.000855	0.00137	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000854	0.00137	CcSEcCtD
Hydroxychloroquine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000852	0.00137	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000851	0.00137	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000845	0.00136	CcSEcCtD
Hydroxychloroquine—Drowsiness—Methotrexate—urinary bladder cancer	0.000842	0.00135	CcSEcCtD
Hydroxychloroquine—Depression—Methotrexate—urinary bladder cancer	0.00084	0.00135	CcSEcCtD
Hydroxychloroquine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000839	0.00135	CcSEcCtD
Hydroxychloroquine—Pain—Cisplatin—urinary bladder cancer	0.000837	0.00134	CcSEcCtD
Hydroxychloroquine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000835	0.00134	CcSEcCtD
Hydroxychloroquine—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000835	0.00134	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00083	0.00133	CcSEcCtD
Hydroxychloroquine—Dizziness—Thiotepa—urinary bladder cancer	0.000825	0.00132	CcSEcCtD
Hydroxychloroquine—Urticaria—Fluorouracil—urinary bladder cancer	0.00082	0.00132	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000816	0.00131	CcSEcCtD
Hydroxychloroquine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00081	0.0013	CcSEcCtD
Hydroxychloroquine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000807	0.00129	CcSEcCtD
Hydroxychloroquine—Weight decreased—Epirubicin—urinary bladder cancer	0.0008	0.00128	CcSEcCtD
Hydroxychloroquine—Somnolence—Etoposide—urinary bladder cancer	0.000797	0.00128	CcSEcCtD
Hydroxychloroquine—Vomiting—Thiotepa—urinary bladder cancer	0.000794	0.00127	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—RBX1—urinary bladder cancer	0.000789	0.00279	CbGpPWpGaD
Hydroxychloroquine—Drowsiness—Epirubicin—urinary bladder cancer	0.000788	0.00126	CcSEcCtD
Hydroxychloroquine—Rash—Thiotepa—urinary bladder cancer	0.000787	0.00126	CcSEcCtD
Hydroxychloroquine—Dermatitis—Thiotepa—urinary bladder cancer	0.000786	0.00126	CcSEcCtD
Hydroxychloroquine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000786	0.00126	CcSEcCtD
Hydroxychloroquine—Headache—Thiotepa—urinary bladder cancer	0.000782	0.00125	CcSEcCtD
Hydroxychloroquine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000781	0.00125	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Etoposide—urinary bladder cancer	0.000779	0.00125	CcSEcCtD
Hydroxychloroquine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000777	0.00125	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000774	0.00124	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000774	0.00124	CcSEcCtD
Hydroxychloroquine—Fatigue—Etoposide—urinary bladder cancer	0.000773	0.00124	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—CREBBP—urinary bladder cancer	0.000769	0.00272	CbGpPWpGaD
Hydroxychloroquine—Pain—Etoposide—urinary bladder cancer	0.000767	0.00123	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—IFNA2—urinary bladder cancer	0.000765	0.0027	CbGpPWpGaD
Hydroxychloroquine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000761	0.00122	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Methotrexate—urinary bladder cancer	0.00076	0.00122	CcSEcCtD
Hydroxychloroquine—Haemorrhage—Methotrexate—urinary bladder cancer	0.000756	0.00121	CcSEcCtD
Hydroxychloroquine—Asthenia—Gemcitabine—urinary bladder cancer	0.000753	0.00121	CcSEcCtD
Hydroxychloroquine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000746	0.0012	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—GLI1—urinary bladder cancer	0.000744	0.00263	CbGpPWpGaD
Hydroxychloroquine—Pruritus—Gemcitabine—urinary bladder cancer	0.000743	0.00119	CcSEcCtD
Hydroxychloroquine—Nausea—Thiotepa—urinary bladder cancer	0.000741	0.00119	CcSEcCtD
Hydroxychloroquine—Weight decreased—Doxorubicin—urinary bladder cancer	0.00074	0.00119	CcSEcCtD
Hydroxychloroquine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000735	0.00118	CcSEcCtD
Hydroxychloroquine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000733	0.00118	CcSEcCtD
Hydroxychloroquine—Pruritus—Fluorouracil—urinary bladder cancer	0.00073	0.00117	CcSEcCtD
Hydroxychloroquine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000729	0.00117	CcSEcCtD
Hydroxychloroquine—Visual impairment—Methotrexate—urinary bladder cancer	0.000729	0.00117	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—S100B—urinary bladder cancer	0.000723	0.00256	CbGpPWpGaD
Hydroxychloroquine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000723	0.00116	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000721	0.00116	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000718	0.00115	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000715	0.00115	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—FGFR3—urinary bladder cancer	0.000714	0.00252	CbGpPWpGaD
Hydroxychloroquine—Urticaria—Etoposide—urinary bladder cancer	0.000712	0.00114	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000711	0.00114	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Etoposide—urinary bladder cancer	0.000709	0.00114	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Etoposide—urinary bladder cancer	0.000709	0.00114	CcSEcCtD
Hydroxychloroquine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000708	0.0025	CbGpPWpGaD
Hydroxychloroquine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000707	0.00114	CcSEcCtD
Hydroxychloroquine—Eye disorder—Methotrexate—urinary bladder cancer	0.000706	0.00113	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000706	0.00113	CcSEcCtD
Hydroxychloroquine—Tinnitus—Methotrexate—urinary bladder cancer	0.000705	0.00113	CcSEcCtD
Hydroxychloroquine—Asthenia—Cisplatin—urinary bladder cancer	0.000702	0.00113	CcSEcCtD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000698	0.00247	CbGpPWpGaD
Hydroxychloroquine—Dizziness—Fluorouracil—urinary bladder cancer	0.000683	0.0011	CcSEcCtD
Hydroxychloroquine—Visual impairment—Epirubicin—urinary bladder cancer	0.000682	0.00109	CcSEcCtD
Hydroxychloroquine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00068	0.00109	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00067	0.00107	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000669	0.00107	CcSEcCtD
Hydroxychloroquine—Alopecia—Methotrexate—urinary bladder cancer	0.000668	0.00107	CcSEcCtD
Hydroxychloroquine—Vomiting—Gemcitabine—urinary bladder cancer	0.000668	0.00107	CcSEcCtD
Hydroxychloroquine—Mental disorder—Methotrexate—urinary bladder cancer	0.000662	0.00106	CcSEcCtD
Hydroxychloroquine—Rash—Gemcitabine—urinary bladder cancer	0.000662	0.00106	CcSEcCtD
Hydroxychloroquine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000661	0.00106	CcSEcCtD
Hydroxychloroquine—Eye disorder—Epirubicin—urinary bladder cancer	0.000661	0.00106	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000661	0.00106	CcSEcCtD
Hydroxychloroquine—Tinnitus—Epirubicin—urinary bladder cancer	0.00066	0.00106	CcSEcCtD
Hydroxychloroquine—Malnutrition—Methotrexate—urinary bladder cancer	0.000658	0.00106	CcSEcCtD
Hydroxychloroquine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000658	0.00106	CcSEcCtD
Hydroxychloroquine—Headache—Gemcitabine—urinary bladder cancer	0.000658	0.00106	CcSEcCtD
Hydroxychloroquine—Vomiting—Fluorouracil—urinary bladder cancer	0.000656	0.00105	CcSEcCtD
Hydroxychloroquine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000655	0.00105	CcSEcCtD
Hydroxychloroquine—Rash—Fluorouracil—urinary bladder cancer	0.000651	0.00104	CcSEcCtD
Hydroxychloroquine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00065	0.00104	CcSEcCtD
Hydroxychloroquine—Headache—Fluorouracil—urinary bladder cancer	0.000647	0.00104	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—ERBB2—urinary bladder cancer	0.000644	0.00228	CbGpPWpGaD
Hydroxychloroquine—Asthenia—Etoposide—urinary bladder cancer	0.000643	0.00103	CcSEcCtD
Hydroxychloroquine—Pruritus—Etoposide—urinary bladder cancer	0.000634	0.00102	CcSEcCtD
Hydroxychloroquine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000631	0.00101	CcSEcCtD
Hydroxychloroquine—Alopecia—Epirubicin—urinary bladder cancer	0.000625	0.001	CcSEcCtD
Hydroxychloroquine—Nausea—Gemcitabine—urinary bladder cancer	0.000624	0.001	CcSEcCtD
Hydroxychloroquine—Vomiting—Cisplatin—urinary bladder cancer	0.000622	0.000999	CcSEcCtD
Hydroxychloroquine—Vision blurred—Methotrexate—urinary bladder cancer	0.00062	0.000995	CcSEcCtD
Hydroxychloroquine—Mental disorder—Epirubicin—urinary bladder cancer	0.00062	0.000995	CcSEcCtD
Hydroxychloroquine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000619	0.000993	CcSEcCtD
Hydroxychloroquine—Rash—Cisplatin—urinary bladder cancer	0.000617	0.00099	CcSEcCtD
Hydroxychloroquine—Dermatitis—Cisplatin—urinary bladder cancer	0.000617	0.000989	CcSEcCtD
Hydroxychloroquine—Malnutrition—Epirubicin—urinary bladder cancer	0.000616	0.000988	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Etoposide—urinary bladder cancer	0.000613	0.000985	CcSEcCtD
Hydroxychloroquine—Nausea—Fluorouracil—urinary bladder cancer	0.000613	0.000984	CcSEcCtD
Hydroxychloroquine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000612	0.000982	CcSEcCtD
Hydroxychloroquine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00061	0.000979	CcSEcCtD
Hydroxychloroquine—Anaemia—Methotrexate—urinary bladder cancer	0.000608	0.000976	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—CREBBP—urinary bladder cancer	0.000608	0.00215	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—IFNA2—urinary bladder cancer	0.000605	0.00214	CbGpPWpGaD
Hydroxychloroquine—Tension—Epirubicin—urinary bladder cancer	0.000604	0.00097	CcSEcCtD
Hydroxychloroquine—Nervousness—Epirubicin—urinary bladder cancer	0.000598	0.00096	CcSEcCtD
Hydroxychloroquine—Dizziness—Etoposide—urinary bladder cancer	0.000593	0.000952	CcSEcCtD
Hydroxychloroquine—Vertigo—Methotrexate—urinary bladder cancer	0.000591	0.000949	CcSEcCtD
Hydroxychloroquine—Leukopenia—Methotrexate—urinary bladder cancer	0.000589	0.000945	CcSEcCtD
Hydroxychloroquine—Nausea—Cisplatin—urinary bladder cancer	0.000581	0.000933	CcSEcCtD
Hydroxychloroquine—Vision blurred—Epirubicin—urinary bladder cancer	0.00058	0.000931	CcSEcCtD
Hydroxychloroquine—Alopecia—Doxorubicin—urinary bladder cancer	0.000578	0.000928	CcSEcCtD
Hydroxychloroquine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000573	0.00092	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—S100B—urinary bladder cancer	0.000572	0.00202	CbGpPWpGaD
Hydroxychloroquine—Convulsion—Methotrexate—urinary bladder cancer	0.00057	0.000915	CcSEcCtD
Hydroxychloroquine—Vomiting—Etoposide—urinary bladder cancer	0.00057	0.000915	CcSEcCtD
Hydroxychloroquine—Malnutrition—Doxorubicin—urinary bladder cancer	0.00057	0.000914	CcSEcCtD
Hydroxychloroquine—Anaemia—Epirubicin—urinary bladder cancer	0.000569	0.000913	CcSEcCtD
Hydroxychloroquine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000566	0.002	CbGpPWpGaD
Hydroxychloroquine—Agitation—Epirubicin—urinary bladder cancer	0.000566	0.000908	CcSEcCtD
Hydroxychloroquine—Rash—Etoposide—urinary bladder cancer	0.000565	0.000907	CcSEcCtD
Hydroxychloroquine—Dermatitis—Etoposide—urinary bladder cancer	0.000565	0.000906	CcSEcCtD
Hydroxychloroquine—Headache—Etoposide—urinary bladder cancer	0.000562	0.000901	CcSEcCtD
Hydroxychloroquine—Tension—Doxorubicin—urinary bladder cancer	0.000559	0.000897	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000556	0.000893	CcSEcCtD
Hydroxychloroquine—Nervousness—Doxorubicin—urinary bladder cancer	0.000553	0.000888	CcSEcCtD
Hydroxychloroquine—Vertigo—Epirubicin—urinary bladder cancer	0.000553	0.000888	CcSEcCtD
Hydroxychloroquine—Leukopenia—Epirubicin—urinary bladder cancer	0.000551	0.000885	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—CDKN1A—urinary bladder cancer	0.00055	0.00194	CbGpPWpGaD
Hydroxychloroquine—TLR7—Innate Immune System—PTEN—urinary bladder cancer	0.000549	0.00194	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000549	0.00194	CbGpPWpGaD
Hydroxychloroquine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000541	0.000869	CcSEcCtD
Hydroxychloroquine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000537	0.000862	CcSEcCtD
Hydroxychloroquine—Convulsion—Epirubicin—urinary bladder cancer	0.000534	0.000856	CcSEcCtD
Hydroxychloroquine—Nausea—Etoposide—urinary bladder cancer	0.000533	0.000855	CcSEcCtD
Hydroxychloroquine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000527	0.000845	CcSEcCtD
Hydroxychloroquine—Anaemia—Doxorubicin—urinary bladder cancer	0.000527	0.000845	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—FGFR3—urinary bladder cancer	0.000526	0.00186	CbGpPWpGaD
Hydroxychloroquine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000526	0.000844	CcSEcCtD
Hydroxychloroquine—Agitation—Doxorubicin—urinary bladder cancer	0.000524	0.00084	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—EP300—urinary bladder cancer	0.000524	0.00185	CbGpPWpGaD
Hydroxychloroquine—Skin disorder—Methotrexate—urinary bladder cancer	0.000522	0.000837	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000521	0.000836	CcSEcCtD
Hydroxychloroquine—Vertigo—Doxorubicin—urinary bladder cancer	0.000512	0.000822	CcSEcCtD
Hydroxychloroquine—Anorexia—Methotrexate—urinary bladder cancer	0.000512	0.000822	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—RBX1—urinary bladder cancer	0.00051	0.0018	CbGpPWpGaD
Hydroxychloroquine—Leukopenia—Doxorubicin—urinary bladder cancer	0.00051	0.000819	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—SRC—urinary bladder cancer	0.000509	0.0018	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—ERBB2—urinary bladder cancer	0.000509	0.0018	CbGpPWpGaD
Hydroxychloroquine—Oedema—Epirubicin—urinary bladder cancer	0.000503	0.000807	CcSEcCtD
Hydroxychloroquine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000501	0.000804	CcSEcCtD
Hydroxychloroquine—Convulsion—Doxorubicin—urinary bladder cancer	0.000494	0.000792	CcSEcCtD
Hydroxychloroquine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000493	0.000791	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000492	0.00079	CcSEcCtD
Hydroxychloroquine—Skin disorder—Epirubicin—urinary bladder cancer	0.000488	0.000783	CcSEcCtD
Hydroxychloroquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000482	0.000773	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—TSC1—urinary bladder cancer	0.00048	0.00169	CbGpPWpGaD
Hydroxychloroquine—Anorexia—Epirubicin—urinary bladder cancer	0.000479	0.000769	CcSEcCtD
Hydroxychloroquine—Somnolence—Methotrexate—urinary bladder cancer	0.000477	0.000766	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000467	0.000749	CcSEcCtD
Hydroxychloroquine—Oedema—Doxorubicin—urinary bladder cancer	0.000465	0.000746	CcSEcCtD
Hydroxychloroquine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000464	0.000744	CcSEcCtD
Hydroxychloroquine—Fatigue—Methotrexate—urinary bladder cancer	0.000463	0.000743	CcSEcCtD
Hydroxychloroquine—Pain—Methotrexate—urinary bladder cancer	0.000459	0.000737	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—JAG1—urinary bladder cancer	0.000457	0.00161	CbGpPWpGaD
Hydroxychloroquine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000456	0.000732	CcSEcCtD
Hydroxychloroquine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000455	0.000731	CcSEcCtD
Hydroxychloroquine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000452	0.000725	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—CREBBP—urinary bladder cancer	0.000448	0.00158	CbGpPWpGaD
Hydroxychloroquine—Somnolence—Epirubicin—urinary bladder cancer	0.000447	0.000717	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—EGFR—urinary bladder cancer	0.000446	0.00158	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—CDH1—urinary bladder cancer	0.000444	0.00157	CbGpPWpGaD
Hydroxychloroquine—Anorexia—Doxorubicin—urinary bladder cancer	0.000443	0.000711	CcSEcCtD
Hydroxychloroquine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000439	0.000705	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000437	0.000701	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—CDKN1A—urinary bladder cancer	0.000435	0.00154	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—PTEN—urinary bladder cancer	0.000434	0.00153	CbGpPWpGaD
Hydroxychloroquine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000434	0.000696	CcSEcCtD
Hydroxychloroquine—Fatigue—Epirubicin—urinary bladder cancer	0.000433	0.000695	CcSEcCtD
Hydroxychloroquine—Pain—Epirubicin—urinary bladder cancer	0.00043	0.00069	CcSEcCtD
Hydroxychloroquine—Urticaria—Methotrexate—urinary bladder cancer	0.000427	0.000685	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000425	0.000681	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000425	0.000681	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—KRAS—urinary bladder cancer	0.000422	0.00149	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—FGFR3—urinary bladder cancer	0.000416	0.00147	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—EP300—urinary bladder cancer	0.000414	0.00146	CbGpPWpGaD
Hydroxychloroquine—Somnolence—Doxorubicin—urinary bladder cancer	0.000413	0.000663	CcSEcCtD
Hydroxychloroquine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000411	0.00066	CcSEcCtD
Hydroxychloroquine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000404	0.000649	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—SRC—urinary bladder cancer	0.000403	0.00142	CbGpPWpGaD
Hydroxychloroquine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000402	0.000644	CcSEcCtD
Hydroxychloroquine—Fatigue—Doxorubicin—urinary bladder cancer	0.000401	0.000643	CcSEcCtD
Hydroxychloroquine—Urticaria—Epirubicin—urinary bladder cancer	0.000399	0.000641	CcSEcCtD
Hydroxychloroquine—Pain—Doxorubicin—urinary bladder cancer	0.000398	0.000638	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000397	0.000638	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000397	0.000638	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000396	0.000635	CcSEcCtD
Hydroxychloroquine—Asthenia—Methotrexate—urinary bladder cancer	0.000385	0.000618	CcSEcCtD
Hydroxychloroquine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000381	0.00134	CbGpPWpGaD
Hydroxychloroquine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00038	0.00061	CcSEcCtD
Hydroxychloroquine—Pruritus—Methotrexate—urinary bladder cancer	0.00038	0.00061	CcSEcCtD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000375	0.00133	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—ERBB2—urinary bladder cancer	0.000375	0.00133	CbGpPWpGaD
Hydroxychloroquine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00037	0.000594	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—S100B—urinary bladder cancer	0.00037	0.00131	CbGpPWpGaD
Hydroxychloroquine—Urticaria—Doxorubicin—urinary bladder cancer	0.000369	0.000593	CcSEcCtD
Hydroxychloroquine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000368	0.00059	CcSEcCtD
Hydroxychloroquine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000368	0.00059	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000367	0.00059	CcSEcCtD
Hydroxychloroquine—Asthenia—Epirubicin—urinary bladder cancer	0.000361	0.000579	CcSEcCtD
Hydroxychloroquine—TLR7—Innate Immune System—HRAS—urinary bladder cancer	0.000358	0.00127	CbGpPWpGaD
Hydroxychloroquine—Pruritus—Epirubicin—urinary bladder cancer	0.000356	0.000571	CcSEcCtD
Hydroxychloroquine—Dizziness—Methotrexate—urinary bladder cancer	0.000355	0.00057	CcSEcCtD
Hydroxychloroquine—TLR9—Immune System—CREBBP—urinary bladder cancer	0.000354	0.00125	CbGpPWpGaD
Hydroxychloroquine—TLR9—Innate Immune System—EGFR—urinary bladder cancer	0.000353	0.00125	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—CDH1—urinary bladder cancer	0.000351	0.00124	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.00035	0.00124	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000345	0.00122	CbGpPWpGaD
Hydroxychloroquine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000344	0.000552	CcSEcCtD
Hydroxychloroquine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000343	0.00055	CcSEcCtD
Hydroxychloroquine—Vomiting—Methotrexate—urinary bladder cancer	0.000341	0.000548	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—IL2—urinary bladder cancer	0.00034	0.0012	CbGpPWpGaD
Hydroxychloroquine—Rash—Methotrexate—urinary bladder cancer	0.000339	0.000543	CcSEcCtD
Hydroxychloroquine—Dermatitis—Methotrexate—urinary bladder cancer	0.000338	0.000543	CcSEcCtD
Hydroxychloroquine—Headache—Methotrexate—urinary bladder cancer	0.000336	0.00054	CcSEcCtD
Hydroxychloroquine—Asthenia—Doxorubicin—urinary bladder cancer	0.000334	0.000535	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—KRAS—urinary bladder cancer	0.000333	0.00118	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—NCOR1—urinary bladder cancer	0.000332	0.00117	CbGpPWpGaD
Hydroxychloroquine—Dizziness—Epirubicin—urinary bladder cancer	0.000332	0.000533	CcSEcCtD
Hydroxychloroquine—Pruritus—Doxorubicin—urinary bladder cancer	0.000329	0.000528	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—CDKN1A—urinary bladder cancer	0.000321	0.00113	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—PTEN—urinary bladder cancer	0.00032	0.00113	CbGpPWpGaD
Hydroxychloroquine—Vomiting—Epirubicin—urinary bladder cancer	0.00032	0.000513	CcSEcCtD
Hydroxychloroquine—Nausea—Methotrexate—urinary bladder cancer	0.000319	0.000512	CcSEcCtD
Hydroxychloroquine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000318	0.000511	CcSEcCtD
Hydroxychloroquine—Rash—Epirubicin—urinary bladder cancer	0.000317	0.000509	CcSEcCtD
Hydroxychloroquine—Dermatitis—Epirubicin—urinary bladder cancer	0.000317	0.000508	CcSEcCtD
Hydroxychloroquine—Headache—Epirubicin—urinary bladder cancer	0.000315	0.000505	CcSEcCtD
Hydroxychloroquine—Dizziness—Doxorubicin—urinary bladder cancer	0.000308	0.000494	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—EP300—urinary bladder cancer	0.000305	0.00108	CbGpPWpGaD
Hydroxychloroquine—Nausea—Epirubicin—urinary bladder cancer	0.000299	0.000479	CcSEcCtD
Hydroxychloroquine—TLR7—Immune System—SRC—urinary bladder cancer	0.000297	0.00105	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—ERBB2—urinary bladder cancer	0.000296	0.00105	CbGpPWpGaD
Hydroxychloroquine—Vomiting—Doxorubicin—urinary bladder cancer	0.000296	0.000475	CcSEcCtD
Hydroxychloroquine—Rash—Doxorubicin—urinary bladder cancer	0.000293	0.000471	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—TERT—urinary bladder cancer	0.000293	0.00104	CbGpPWpGaD
Hydroxychloroquine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000293	0.00047	CcSEcCtD
Hydroxychloroquine—Headache—Doxorubicin—urinary bladder cancer	0.000291	0.000468	CcSEcCtD
Hydroxychloroquine—TLR9—Innate Immune System—HRAS—urinary bladder cancer	0.000283	0.001	CbGpPWpGaD
Hydroxychloroquine—Nausea—Doxorubicin—urinary bladder cancer	0.000276	0.000443	CcSEcCtD
Hydroxychloroquine—TLR9—Signaling Pathways—FGFR3—urinary bladder cancer	0.000269	0.00095	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—IL2—urinary bladder cancer	0.000269	0.000949	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—ESR1—urinary bladder cancer	0.000261	0.000923	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—EGFR—urinary bladder cancer	0.00026	0.000919	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—CDKN1A—urinary bladder cancer	0.000253	0.000895	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—PTEN—urinary bladder cancer	0.000253	0.000893	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—KRAS—urinary bladder cancer	0.000246	0.000868	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—EP300—urinary bladder cancer	0.000241	0.000852	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—SRC—urinary bladder cancer	0.000234	0.000828	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000233	0.000824	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—CREBBP—urinary bladder cancer	0.000229	0.000809	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—IGF1—urinary bladder cancer	0.000226	0.000799	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000221	0.000781	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000221	0.000781	CbGpPWpGaD
Hydroxychloroquine—TLR7—Immune System—HRAS—urinary bladder cancer	0.000209	0.000738	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—RHOA—urinary bladder cancer	0.000207	0.000732	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—EGFR—urinary bladder cancer	0.000205	0.000726	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000202	0.000714	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—KRAS—urinary bladder cancer	0.000194	0.000686	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—ERBB2—urinary bladder cancer	0.000192	0.000677	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000182	0.000643	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—CXCL8—urinary bladder cancer	0.000182	0.000642	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—IL2—urinary bladder cancer	0.000174	0.000614	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000172	0.000607	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—CCND1—urinary bladder cancer	0.000169	0.000598	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000167	0.000592	CbGpPWpGaD
Hydroxychloroquine—TLR9—Immune System—HRAS—urinary bladder cancer	0.000165	0.000583	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—MMP9—urinary bladder cancer	0.000164	0.000581	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000164	0.000579	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—PTEN—urinary bladder cancer	0.000163	0.000578	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—EP300—urinary bladder cancer	0.000156	0.000551	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—SRC—urinary bladder cancer	0.000152	0.000536	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—MYC—urinary bladder cancer	0.000136	0.00048	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	0.000134	0.000473	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—EGFR—urinary bladder cancer	0.000133	0.000469	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—KRAS—urinary bladder cancer	0.000126	0.000444	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	0.000121	0.000428	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—TP53—urinary bladder cancer	0.000112	0.000394	CbGpPWpGaD
Hydroxychloroquine—TLR9—Signaling Pathways—HRAS—urinary bladder cancer	0.000107	0.000377	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	0.000105	0.000369	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.68e-05	0.000342	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.68e-05	0.000342	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.39e-05	0.000332	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.8e-05	0.000276	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.51e-05	0.00023	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.05e-05	0.000214	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	5.98e-05	0.000211	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	5.98e-05	0.000211	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.73e-05	0.000202	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.62e-05	0.000199	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.29e-05	0.000187	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.29e-05	0.000151	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.12e-05	0.000146	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.37e-05	0.000119	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.94e-05	0.000104	CbGpPWpGaD
Hydroxychloroquine—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.8e-05	9.91e-05	CbGpPWpGaD
